| 產(chǎn)品名稱 | HAMNO - NSC 111847 |
| 產(chǎn)品貨號 | Axon 2390 CAS [138736-73-9] MF C17H13NO2MW 263.29 Purity: 99% Soluble in DMSO Description Novel protein interaction inhibitor of replication protein A (RPA), a protein involved in the ATR/Chk1 pathway. HAMNO selectively binds the N-terminal DBD-F domain of RPA70, effectively inhibiting critical RPA protein interactions that rely on this domain. HAMNO inhibits both ATR autophosphorylation and phosphorylation of RPA32 Ser33 by ATR. Candidate therapeutic for cancer treatment, as it enhances the constitutive and oncogene-induced replication stress in cancer cells. References Certificates Categories Extra info J.G. Glanzer et al. RPA inhibition increases replication stress and suppresses tumor growth. Cancer Res. 2014 Sep 15;74(18):5165-72. Certificate of Analysis Material Safety Data Sheet Apoptosis Cell Cycle Regulation Cell Signaling & Oncology DNA-damage Response RPA Novel protein interaction inhibitor of replication protein A (RPA) Chemical name (Z)-1-((2-hydroxyphenylamino)methylene)naphthalen-2(1H)-one Parent CAS No. [138736-73-9] Order Size Unit Price Stock 10 mg €85.00 In Stock |
| 產(chǎn)品價格 | 現(xiàn)貨詢價，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
HAMNO - NSC 111847Axon 2390 CAS [138736-73-9] MF C17H13NO2
Description
Novel protein interaction inhibitor of replication protein A (RPA), a protein involved in the ATR/Chk1 pathway. HAMNO selectively binds the N-terminal DBD-F domain of RPA70, effectively inhibiting critical RPA protein interactions that rely on this domain. HAMNO inhibits both ATR autophosphorylation and phosphorylation of RPA32 Ser33 by ATR. Candidate therapeutic for cancer treatment, as it enhances the constitutive and oncogene-induced replication stress in cancer cells.
Novel protein interaction inhibitor of replication protein A (RPA)
Chemical name(Z)-1-((2-hydroxyphenylamino)methylene)naphthalen-2(1H)-one Parent CAS No.[138736-73-9] |
| 產(chǎn)品資料 |
